Mirum Pharmaceuticals (NASDAQ:MIRM) Hits New 52-Week High – Should You Buy?

Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM)’s share price reached a new 52-week high during trading on Wednesday . The stock traded as high as $83.75 and last traded at $81.9450, with a volume of 523226 shares. The stock had previously closed at $76.46.

Analysts Set New Price Targets

A number of equities analysts have issued reports on MIRM shares. Citigroup reiterated an “outperform” rating on shares of Mirum Pharmaceuticals in a research report on Friday, December 19th. Cowen initiated coverage on Mirum Pharmaceuticals in a research report on Wednesday, September 24th. They set a “buy” rating on the stock. Evercore ISI lifted their price target on shares of Mirum Pharmaceuticals from $89.00 to $94.00 and gave the company an “outperform” rating in a research note on Monday, December 8th. Robert W. Baird increased their price objective on shares of Mirum Pharmaceuticals from $80.00 to $88.00 and gave the company an “outperform” rating in a report on Monday, December 8th. Finally, TD Cowen upgraded shares of Mirum Pharmaceuticals to a “strong-buy” rating in a research report on Thursday, September 25th. Two analysts have rated the stock with a Strong Buy rating, twelve have assigned a Buy rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, Mirum Pharmaceuticals presently has an average rating of “Buy” and a consensus price target of $100.25.

Mirum Pharmaceuticals Trading Up 6.1%

The company has a market cap of $4.45 billion, a PE ratio of -100.66 and a beta of 0.48. The company’s 50 day simple moving average is $72.92 and its two-hundred day simple moving average is $67.73. The company has a debt-to-equity ratio of 1.06, a current ratio of 3.31 and a quick ratio of 3.16.

Mirum Pharmaceuticals (NASDAQ:MIRM) last issued its quarterly earnings data on Tuesday, November 4th. The company reported $0.05 EPS for the quarter, topping the consensus estimate of ($0.10) by $0.15. The firm had revenue of $133.01 million for the quarter, compared to analyst estimates of $130.11 million. Mirum Pharmaceuticals had a negative net margin of 8.78% and a negative return on equity of 16.47%. The business’s revenue for the quarter was up 47.1% compared to the same quarter last year. During the same period in the prior year, the business posted ($0.30) EPS. As a group, sell-side analysts anticipate that Mirum Pharmaceuticals, Inc. will post -1.43 EPS for the current fiscal year.

Institutional Inflows and Outflows

Institutional investors have recently made changes to their positions in the business. SG Americas Securities LLC purchased a new position in shares of Mirum Pharmaceuticals in the 4th quarter valued at about $1,478,000. NorthCrest Asset Manangement LLC acquired a new stake in shares of Mirum Pharmaceuticals during the 4th quarter worth about $406,000. Tudor Investment Corp ET AL purchased a new stake in Mirum Pharmaceuticals during the third quarter worth approximately $2,027,000. CIBC Bancorp USA Inc. purchased a new stake in Mirum Pharmaceuticals during the third quarter worth approximately $315,000. Finally, PharVision Advisers LLC acquired a new position in Mirum Pharmaceuticals in the third quarter valued at approximately $273,000.

Mirum Pharmaceuticals Company Profile

Mirum Pharmaceuticals, Inc is a late-stage biopharmaceutical company dedicated to the development and commercialization of innovative therapies for rare cholestatic liver diseases. The company’s primary focus lies in addressing the unmet medical needs of patients suffering from genetic and progressive forms of pediatric liver disorders, where limited treatment options currently exist.

Mirum’s lead product candidate, maralixibat (Livmarli), is an ileal bile acid transporter inhibitor designed to reduce systemic bile acid accumulation and alleviate associated pruritus and liver damage.